Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
NCT ID: NCT00169572
Last Updated: 2010-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
492 participants
INTERVENTIONAL
2005-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
NCT00104403
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
NCT00891761
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
NCT00431236
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
NCT00366834
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
NCT01857232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aprepitant
Ondansetron
GW679769
Dexamethasone
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with a solid malignant tumour and has not previously received chemotherapy.
* Scheduled to receive chemotherapy conducive to regimens outlined in the study protocol.
Exclusion Criteria
* Must not be pregnant.
* Must not be of childbearing potential or is willing to use specific barrier methods outlined in the protocol.
* Must not be scheduled to receive radiation therapy to the abdomen or to the pelvis within seven (7) days prior to starting study medication.
* Must not be currently under treatment for a condition which may cause nausea or vomiting (i.e., active peptic ulcer disease, gastric obstruction).
* Must not have a history of peptic ulcer disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GSK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, MD
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Salzburg, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Edegem, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Liège, , Belgium
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Zagreb, , Croatia
GSK Investigational Site
Hradec Králové, , Czechia
GSK Investigational Site
Ostrava - Poruba, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Shatin, N.T., , Hong Kong
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Székesfehérvár, , Hungary
GSK Investigational Site
Benevento, Campania, Italy
GSK Investigational Site
Napoli, Campania, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Casalpusterlengo (LO), Lombardy, Italy
GSK Investigational Site
Sassari, Sardinia, Italy
GSK Investigational Site
Pisa, Tuscany, Italy
GSK Investigational Site
Perugia, Umbria, Italy
GSK Investigational Site
Durango, Durango, Mexico
GSK Investigational Site
Mérida, Yucatán, Mexico
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Arnhem, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Utrecht, , Netherlands
GSK Investigational Site
Karachi, , Pakistan
GSK Investigational Site
Lahore, , Pakistan
GSK Investigational Site
Callao, Provincia Constitucional del Callao, Peru
GSK Investigational Site
Quezon City, , Philippines
GSK Investigational Site
Taft Avenue, Manila, , Philippines
GSK Investigational Site
Bydogoszcz, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Poznan, , Poland
GSK Investigational Site
Poznan, , Poland
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Singapore, , Singapore
GSK Investigational Site
Košice, , Slovakia
GSK Investigational Site
Nitra, , Slovakia
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Tao Yuan County, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKV20001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.